镰状细胞病患儿入住儿科重症监护病房不良结局的相关因素:一项观察性队列研究
该回顾性队列研究纳入法国一家三级医院2009年1月1日至2019年12月31日连续收治的镰状细胞病患儿PICU入住记录,共579次入住、395例患者,主要基因型为SS(90%),中位年龄9.2岁[5.5-13.4],中位基线血红蛋白8.0 g/dl(7.5-8.8)。入住原因主要为急性胸部综合征(331次,57%)和对一线治疗无反应的血管闭塞危象(99次,17%)。113次(20%)入住发生不良结局,多变量分析显示基线血红蛋白<8 g/dL、支气管阻塞史和因急性胸部综合征入院与不良结局相关;羟基脲治疗或交换输血项目在不良结局组与其他患者间无差异。
要点
- 579次PICU入住中113次(20%)发生不良结局,7例(1%)在PICU期间死亡。
- 多变量分析显示基线血红蛋白<8 g/dL、支气管阻塞史和因急性胸部综合征入院与不良结局相关。
- 入住原因以急性胸部综合征(331次,57%)和对一线治疗无反应的血管闭塞危象(99次,17%)为主。
- 半数患者需要无创通气,47例(8%)需要有创机械通气,总体住院时间3天[1-4]。
- 羟基脲治疗或交换输血项目在不良结局组与其他患者间无差异。
适用人群与场景
- 法国一家三级医院2009年1月1日至2019年12月31日连续收治的镰状细胞病患儿,共579次PICU入住、395例患者,主要基因型为SS(90%),中位年龄9.2岁[5.5-13.4]。
诊断标准与关键阈值
- 不良结局定义为:PICU住院期间死亡和/或需要有创机械通气(MV)和/或无创通气(NIV)超过3天和/或需要血管升压药和/或需要肾脏替代治疗。
研究设计与关键结果
- 回顾性观察性队列研究,纳入579次PICU入住(395例患者),中位基线血红蛋白8.0 g/dl(7.5-8.8)。
- 入住原因:急性胸部综合征331次(57%),对一线治疗无反应的血管闭塞危象99次(17%)。
- 半数患者需要无创通气,47例(8%)需要有创机械通气;总体住院时间3天[1-4];7例(1%)在PICU期间死亡。
- 113次(20%)入住发生不良结局;多变量分析显示基线血红蛋白<8 g/dL、支气管阻塞史和因急性胸部综合征入院与不良结局相关。
- 羟基脲治疗或交换输血项目在不良结局组与其他患者间无差异。
证据类型、等级与局限
- 证据类型:回顾性观察性队列研究;局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,基线血红蛋白<8 g/dL、支气管阻塞史和因急性胸部综合征入院是镰状细胞病患儿入住PICU后严重演变的最强危险因素,选择适当治疗方案时可考虑这些因素。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Sickle cell disease (SCD) is one of the most frequent inherited diseases in the world. Over the last decades, in high-income countries, an important decrease in mortality have been observed due to the improvement of care. However, children with SCD can become critically ill and require admission in Pediatric Intensive Care Units (PICU). The purpose of this study was to describe the epidemiology of children with SCD admitted to PICU for acute crisis and to identify factors associated with adverse outcome (AO).
METHODS: We conducted a retrospective study in a Tertiary Hospital in France including all consecutive children with SCD admitted to PICU between January 1st, 2009 and December 31, 2019. We collected baseline patient's characteristics, clinical and biological data as well as treatments and life sustaining therapies used in the PICU. Patients were defined as experiencing AO in case of death during stay and/or need for invasive mechanical ventilation (MV) and/or for non-invasive ventilation (NIV) for more than 3 days and/or need for vasopressors and/or need for renal replacement therapy.
RESULTS: We included 579 admissions in 395 patients, mainly of SS genotype (90%) with a median age of 9.2 years [5.5-13.4] and a median baseline hemoglobin of 8.0 g/dl (7.5-8.8). The two main reasons for admission were acute chest syndrome (ACS) (n = 331, 57%) and vaso-occlusive crisis refractory to first line therapy (n = 99, 17%). Half of patients required NIV and 47 (8%) required MV. The overall length of stay was 3 days [1-4] and seven (1%) patients died during PICU stay.There was a total of 113 (20%) admissions with AO and on multivariable analysis, baseline hemoglobin < 8 g/dL, history of bronchial obstruction and admission for ACS were associated with AO. There was no difference in the proportion of hydroxyurea treatment or exchange transfusion program between patients with AO and the other patients.
CONCLUSIONS: Baseline hemoglobin < 8 g/dL, history of bronchial obstruction and admission for ACS were the strongest risk factors for severe evolution in SCD children admitted to PICU. These factors could be taken into consideration when choosing the adequate therapeutic options.
参考来源
- Levy M, Naudin J, Geslain G, et al. Factors associated with adverse outcome among children with sickle cell disease admitted to the pediatric intensive care unit: an observational cohort. Ann Intensive Care. 2024. PMID: 38594419. doi:10.1186/s13613-024-01283-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。